September 7, 2021Open Access

Sodium restriction in patients with chronic heart failure and reduced ejection fraction: A randomized controlled trial

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Chronic heart failure with reduced ejection fraction (n=70). Intervention: Sodium restriction vs. Control group (3 g of sodium/day). Primary outcome: Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 20 weeks (null, 95% CI null, p=0.88).

JIJuan B. Ivey‐MirandaHeart Failure & Transplant EAEduardo Almeida‐GutiérrezCentro Medico Nacional Siglo XXI RHRaúl Herrera-SaucedoMexican Social Security Institute

Resultado clave

Patients who achieved a sodium intake < 2500 mg/day showed improvements in NT-proBNP levels by 55% and quality of life by 11 ± 5 points compared to those with higher sodium intake.

Diseño del estudio

Tipo

RCT (n=70)

Enmascaramiento

Double-blind

Aleatorización

Simple sequential randomization

Multicéntrico

PICO

Población

Chronic heart failure with reduced ejection fraction (n=70)

Intervención / comparador

Sodium restriction vs Control group (3 g of sodium/day) (2 g of sodium/day)

Resultado principal

Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 20 weeks — null (null), p=0.88

Resultado numérico

Estimación del efecto: null (95% CI null)

Tasa de eventos absoluta: 882% vs 569%

valor p: p=0.88

Limitaciones

Relative small sample size, thus results should be interpreted cautiously.
Baseline sodium intake was not excessively high; therefore, results may not extrapolate to patients with higher sodium intake.
Adherence was assessed only four times during the 20-week period, which may not accurately reflect dietary changes.

Resumen

gov Identifier: NCT03351283.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Ivey‐Miranda et al. (Tue,) conducted a rct in Chronic heart failure with reduced ejection fraction (n=70). Sodium restriction vs. Control group (3 g of sodium/day) was evaluated on Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 20 weeks (null, 95% CI null, p=0.88). Patients who achieved a sodium intake < 2500 mg/day showed improvements in NT-proBNP levels by 55% and quality of life by 11 ± 5 points compared to those with higher sodium intake.

synapsesocial.com/papers/696b83063d9324fa0eadb422 https://doi.org/https://doi.org/10.5603/cj.a2021.0098

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: